Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT04718181
- Locations
- 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States
🇺🇸Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 474
- Registration Number
- NCT04712097
- Locations
- 🇦🇺
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia
🇫🇷Institut Paoli Calmettes, Marseille, France
🇩🇪Medizinische Klinik IV, Hämatologie Universitätsklinikum Gießen, Giessen, Germany
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 342
- Registration Number
- NCT04712643
- Locations
- 🇨🇳
Beijing You An Hospital; Digestive Dept, Beijing City, China
🇨🇳The 900th Hospital of PLA joint service support force, Fuzhou, China
🇨🇳Peking University First Hospital, Beijing City, China
Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT04709835
- Locations
- 🇱🇻
The Family Physician's Practice of Dr. Maija Kozlovska, Salaspils, Latvia
🇨🇦Hamilton Medical Research Group, Hamilton, Ontario, Canada
🇮🇪Connolly Hospital, Dublin, Ireland
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 162
- Registration Number
- NCT04677504
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT04665856
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, China
🇨🇳Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT04665843
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States
🇺🇸MD Anderson Cancer Center; Oncology, Houston, Texas, United States
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT04661150
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China
🇨🇳First Hospital of China Medical University; Surgery, Shenyang City, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04660799
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun City, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou City, China
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT04660539
- Locations
- 🇺🇸
Jefferson Hospital For Neuroscience; Jefferson Neurology Associates, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States